Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24031694 | 0.91 | — | — | |
| SCHEMBL23551954 | 0.91 | HRH3 (0.33) | — | |
| SCHEMBL22363525 | 0.84 | OPRL1 (0.36) | OPRM1OPRL1 | |
| SCHEMBL25090085 | 0.82 | HRH3 (0.35) | — | |
| SCHEMBL24827975 | 0.81 | HRH3 (0.30) | — | |
| SCHEMBL22857746 | 0.80 | OPRM1 (0.31) | OPRM1OPRL1 | |
| SCHEMBL23374118 | 0.79 | HRH3 (0.36) | OPRM1OPRL1 | |
| SCHEMBL22645192 | 0.78 | HRH3 (0.30) | — | |
| SCHEMBL27053956 | 0.78 | OPRM1 (0.35) | OPRM1OPRL1 | |
| SCHEMBL26328605 | 0.78 | CYP2D6 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220129-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-20200354357-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| US-10711000-B2 | Autotaxin inhibitors and uses thereof | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711000-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | OPRM1 4817/4885OPRL1 4461/4885 |
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | OPRM1 4817/4885OPRL1 4461/4885 |
| US-20200354357-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, RNASE1 | OPRM1 4817/4885OPRL1 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.